SCHEMBL2250434

SCHEMBL2250434

CC#CCN(C(=O)Nc1cc(C(N)=O)c(F)cc1F)C1CCN(Cc2ccc(Oc3ccc(NS(C)(=O)=O)cc3)nc2C)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.36
CDK8 P49336 2/20 0.36
CDK1 P06493 1/20 0.36
CCR5 P51681 6/20 0.35
KCNH2 Q12809 2/20 0.35
CCR4 P51679 2/20 0.32
TRPV1 Q8NER1 3/20 0.32
TP53 P04637 2/20 0.32
LMNA P02545 1/20 0.32
UBE2M P61081 1/20 0.31
DCUN1D1 Q96GG9 1/20 0.31
THRB P10828 1/20 0.31
SRC P12931 2/20 0.31
MCHR1 Q99705 1/20 0.31
STK25 O00506 1/20 0.31
CIT O14578 1/20 0.31
MAP2K7 O14733 1/20 0.31
IKBKB O14920 1/20 0.31
AURKA O14965 1/20 0.31
GAK O14976 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2254899 0.93 CDK1 (0.35) CDK2CDK8CDK1CCR5KCNH2
SCHEMBL2251515 0.93 CDK2 (0.35) CDK2CDK8CDK1CCR5TRPV1
SCHEMBL2252035 0.93 CDK1 (0.35) CDK2CDK8CDK1TRPV1MCHR1
SCHEMBL2253313 0.92 CCR5 (0.36) CDK2CDK8CDK1CCR5KCNH2
SCHEMBL2252142 0.91 CCR5 (0.35) CDK2CDK8CDK1CCR5KCNH2
SCHEMBL2250463 0.91 CCR5 (0.35) CDK2CDK8CDK1CCR5KCNH2
SCHEMBL2251435 0.91 CDK2 (0.38) CDK2CDK8CDK1CCR5KCNH2
SCHEMBL2247960 0.91 CDK1 (0.37) CDK2CDK8CDK1CCR5KCNH2
SCHEMBL2253261 0.89 CDK2 (0.36) CDK2CDK8CDK1CCR5KCNH2
SCHEMBL2250894 0.89 CDK1 (0.36) CDK2CDK8CDK1CCR5KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003642-B2 Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2011-08-23 US claimed
US-8003642-B2 Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2011-08-23 US disclosed
US-20090131403-A1 NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1995246-A1 NITROGENATED HETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131403-A1 NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT CXCR3, CCR5, HLA-DRB1 CDK2 641/4885CDK8 590/4885CDK1 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.